Case Series: Inotuzumab Salvage Therapy for Relapsed B-ALL After CAR-T and HSCT

A small clinical study has delivered an unexpectedly strong signal in one of leukemia medicine’s most difficult treatment situations: three patients with B-cell acute lymphoblastic leukemia (B-ALL) who had relapsed after both chimeric antigen receptor T-cell therapy and an allogeneic stem-cell transplant were treated with the targeted drug inotuzumab ozogamicin. All three entered bone-marrow remission after a single treatment cycle, and laboratory testing found no measurable residual disease, according to a case series published in Cancer Reports. The results do not establish that the drug can reliably control this aggressive form of leukemia, but they offer a potential rescue option for patients whose disease has already escaped two of the most powerful modern therapies.

B-ALL is a fast-growing cancer in which immature B-cell precursors accumulate in the bone marrow, crowding out the normal cells responsible for producing oxygen-carrying red blood cells, infection-fighting white blood cells and clot-forming platelets. Relapsed disease is particularly difficult to treat. Conventional chemotherapy produces complete remission in only about 31 to 44 percent of adults receiving a first salvage treatment for an early relapse, and remission rates fall to roughly 18 to 25 percent when treatment is attempted later. CAR-T therapy, which genetically equips a patient’s T cells to recognize and destroy leukemia cells, can initially induce remission in 80 to 90 percent of patients. Yet relapse occurs in approximately 30 to 60 percent of cases, sometimes because the engineered cells do not persist or because leukemia cells alter or lose the target recognized by the therapy.

An allogeneic hematopoietic stem-cell transplant can strengthen disease control after CAR-T treatment by replacing the patient’s blood-forming system and creating a new immune response against leukemia. Even so, relapse after transplantation remains the leading cause of death in this population. Adults with B-ALL who relapse after an allogeneic transplant have historically had a median overall survival of only about 5.5 months, with survival at five years estimated at roughly 8 percent. Patients who have failed both CAR-T treatment and transplantation are often profoundly immunosuppressed, infected or suffering from persistent low blood-cell counts. Their leukemia may also resist multiple drugs and appear outside the bone marrow, including in the central nervous system, breast tissue or other organs. The investigators therefore looked for a treatment that could attack leukemia through a mechanism independent of T-cell activity and donor immune recognition.

Inotuzumab ozogamicin is an antibody-drug conjugate, a molecular “guided missile” that combines selective recognition with a highly potent toxin. Its antibody component binds CD22, a protein displayed on the surface of most malignant B cells. Once attached, the leukemia cell internalizes the antibody-drug complex. Inside the cell, the conjugate releases calicheamicin, a cytotoxic compound that causes severe DNA damage, including double-strand breaks. The damaged cell activates apoptosis, a programmed form of cellular suicide. Because the drug acts directly through CD22 and does not require living immune cells to form an attack, it can be used as an “off-the-shelf” treatment rather than a patient-specific cellular product. It also avoids the cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome commonly associated with CAR-T therapy, although it carries its own risks, particularly suppression of blood-cell production and liver injury.

The three patients were treated at one center between September 2019 and October 2021. Each had Philadelphia chromosome-negative B-ALL, confirmed CD22 expression on leukemia blasts, an ECOG performance status of 3 or better, and no active severe graft-versus-host disease. Their leukemia had already returned after CAR-T therapy and an allogeneic transplant. The patients were 53, 16 and 29 years old, all female, and had received between multiple prior treatments. Before inotuzumab, bone-marrow blast levels were 20, 80 and 83 percent, respectively. One patient had no disease outside the marrow, another had extensive involvement at multiple sites, and the third had central nervous system disease. Each received two inotuzumab cycles, with a total dose of 1.8 milligrams per square meter in the first cycle and 1.5 milligrams per square meter in the second.

The response was rapid and deep in all three cases. After the first cycle, each patient achieved complete remission or complete remission with incomplete blood-count recovery, and sensitive testing detected no measurable residual disease in the bone marrow. That test is important because a conventional microscope may show no leukemia even when a small population of malignant cells remains. Flow cytometry and molecular assays can identify residual leukemia at much lower levels, and MRD positivity is strongly associated with an increased risk of relapse. The drug also produced a striking response outside the marrow in the 16-year-old patient, whose leukemia had spread extensively. Positron-emission tomography combined with computed tomography showed that most metabolically active lesions became substantially smaller and less avid for fluorodeoxyglucose after one cycle, indicating a major reduction in active disease. The finding suggests that CD22-directed treatment can reach bulky extramedullary leukemia as well as circulating and marrow-resident blasts.

The remissions, however, were not uniformly durable. The first patient developed molecular progression, with the level of her E2A::PBX1 leukemia marker rising from 0.033 percent to 8.52 percent, followed by a central nervous system relapse eight months after starting inotuzumab. Cerebrospinal-fluid testing showed that lymphoblasts accounted for 37.34 percent of cells. The second patient relapsed 9.5 months after treatment began, with leukemia infiltrating the breast, even though her bone marrow and cerebrospinal fluid remained in remission. The third patient remained leukemia-free at the latest follow-up, 13.5 months after treatment initiation. These outcomes illustrate both the power and the limitation of the approach: inotuzumab can rapidly reduce a large leukemia burden and eliminate detectable marrow disease, but monotherapy may not eradicate every resistant clone or prevent later sanctuary-site relapse.

The safety findings were encouraging but require careful interpretation. No patient died from a treatment-emergent adverse event or stopped therapy because of toxicity. The principal complication was pancytopenia, a broad reduction in white cells, neutrophils, hemoglobin and platelets. All three patients developed severe leukopenia, neutropenia and thrombocytopenia requiring growth-factor support and platelet transfusions; two needed red-cell transfusions for severe anemia. Some of this toxicity may have reflected their already damaged marrow and extensive previous treatment rather than inotuzumab alone. Liver effects were comparatively mild, consisting mainly of grade 1 or 2 increases in alanine aminotransferase, aspartate aminotransferase or bilirubin. Most notably, none developed sinusoidal obstruction syndrome, a potentially fatal form of liver injury associated with inotuzumab, particularly around transplantation. The absence of this complication may have been related to preventive ursodeoxycholic acid, the small number of treatment cycles and patient-specific factors, but three cases are far too few to define the drug’s true risk.

The study also highlights why treatment selection after CAR-T and transplantation must be biologically individualized. Two patients experienced loss of human-leukocyte-antigen markers at relapse. Such loss can allow leukemia to evade recognition by donor immune cells, making donor lymphocyte infusion or donor-derived CAR-T approaches less effective. Inotuzumab and other antibody-based therapies do not depend on HLA matching and can therefore remain active when immune recognition has failed. The investigators favored inotuzumab over blinatumomab because the patients had high marrow blast counts or extensive disease outside the marrow; blinatumomab’s performance is known to decline with a high tumor burden, whereas inotuzumab has shown activity across a broader range of disease levels. Still, the authors emphasize that the study is retrospective and includes only three people, preventing meaningful statistical analysis or broad claims about survival. The results are best viewed as an early clinical signal that may support larger prospective trials, particularly testing inotuzumab alongside lower-intensity chemotherapy, blinatumomab, donor-cell strategies when biologically appropriate or a second transplant when remission can be achieved.